Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any autosomal dominant non-syndromic intellectual disability in which the cause of the disease is a mutation in the HIVEP2 gene.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 10 | Dystonia, Seizure, Ataxia |
Digestive system | 3 | Gastroesophageal reflux, Feeding difficulties, Chronic constipation |
Head and neck | 3 | Microcephaly, Thin upper lip vermilion, High palate |
Muscles | 2 | Low muscle tone (hypotonia), Frontal cortical atrophy |
Arms and legs | 1 | Tapered finger |
Growth and development | 1 | Failure to thrive |
HIVEP2 encodes HIVEP zinc finger 2 (2,446 aa). This protein specifically binds to the DNA sequence 5'-GGGACTTTCC-3' which is found in the enhancer elements of numerous viral promoters such as those of SV40, CMV, or HIV1. Highest expression in Brain Cerebellar Hemisphere (38.0 TPM) and Brain Cerebellum (29.0 TPM).
Intellectual disability, autosomal dominant 43 is associated with mutations in the HIVEP2 gene on chromosome 6.
HIVEP2 is classified as a druggable target (Transcription Factor category) with score 13.1.
Genetic testing for HIVEP2 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 3 always present features, 39 common features.
No clinical trials have been registered for intellectual disability, autosomal dominant 43.
11 publications have been identified in PubMed for intellectual disability, autosomal dominant 43. Research spans Case Report / Case Series (55%), Epidemiology / Natural History (27%), and Review / Meta-Analysis (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 55% |
Disease patterns and progression | 3 | 27% |
Research summaries | 1 | 9% |
Laboratory research | 1 | 9% |
Pan X (2026). [PMID: 41764152](https://pubmed.ncbi.nlm.nih.gov/41764152/). *Journal of molecular medicine (Berlin, Germany)*. [Epidemiology / Natural History]
Zhu Z (2026). [PMID: 41808101](https://pubmed.ncbi.nlm.nih.gov/41808101/). *BMC Pediatr*. [Case Report / Case Series]
Xuan X (2026). [PMID: 42091191](https://pubmed.ncbi.nlm.nih.gov/42091191/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Case Report / Case Series]
Manav Yiğit Z (2026). [PMID: 41320952](https://pubmed.ncbi.nlm.nih.gov/41320952/). *Balkan medical journal*. [Basic Science / Preclinical]
Spirito G (2026). [PMID: 41629344](https://pubmed.ncbi.nlm.nih.gov/41629344/). *NPJ Genom Med*. [Epidemiology / Natural History]
Wang Z (2026). [PMID: 41916888](https://pubmed.ncbi.nlm.nih.gov/41916888/). *Zhonghua Yi Xue Yi Chuan Xue Za Zhi*. [Review / Meta-Analysis]
Wang F (2025). [PMID: 40123818](https://pubmed.ncbi.nlm.nih.gov/40123818/). *International journal of general medicine*. [Case Report / Case Series]
D'Incal CP (2025). [PMID: 41214838](https://pubmed.ncbi.nlm.nih.gov/41214838/). *Clinical epigenetics*. [Case Report / Case Series]
Mitsutake A (2024). [PMID: 39730866](https://pubmed.ncbi.nlm.nih.gov/39730866/). *Cerebellum (London, England)*. [Case Report / Case Series]
Dolu MH (2024). [PMID: 39051604](https://pubmed.ncbi.nlm.nih.gov/39051604/). *Journal of child neurology*. [Case Report / Case Series]
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 5:41 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center